Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLD-fX in Seasonal Allergic Rhinitis
NCT00726401Phase 2Completed
- Sponsor
- CV Technologies
- Start
- May 2008
- Primary completion
- Sep 2010
- Modality
- BDS (Botanical Dietary Supplement)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in seasonal allergic rhinitis (SAR) comparing COLD-fX with Placebo (2 arms). Primary endpoint: Preliminary estimates of treatment effect of CVT-E002 in improving quality of life and reducing symptoms at 4 weeks. Started May 2008; status: completed.
02
Drugs
panax quinquefolius
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT00726401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00726401.